排名 |
分析师 |
机构 |
行业 |
年度收益率
|
6个月收益率
|
3个月收益率
|
正收益比例
|
成分股数量
|
历史最大跌幅
|
更新日期
|
1 |
阳景
|
浦银国际证券 |
医药生物 |
61.08%
|
55.43%
|
30.72%
|
100.00%
|
3 |
0.00%
|
2025-07-28 |
2 |
刘浩
|
华创证券 |
医药生物 |
60.74%
|
62.42%
|
38.66%
|
20.00%
|
2 |
-47.33%
|
2025-06-25 |
3 |
刘浩
|
华创证券 |
医药生物 |
60.45%
|
57.07%
|
28.38%
|
20.00%
|
2 |
-47.33%
|
2025-06-19 |
4 |
唐寅灏
|
中信证券 |
医药生物 |
60.38%
|
65.26%
|
31.77%
|
60.00%
|
13 |
-8.47%
|
2025-07-14 |
5 |
阳景
|
浦银国际证券 |
医药生物 |
59.99%
|
54.38%
|
26.82%
|
100.00%
|
3 |
0.00%
|
2025-08-01 |
6 |
胡晨曦
|
长城国瑞证券 |
医药生物 |
59.92%
|
56.96%
|
39.94%
|
3.45%
|
7 |
-27.10%
|
2025-05-21 |
7 |
刘浩
|
华创证券 |
医药生物 |
59.87%
|
55.35%
|
27.55%
|
20.00%
|
2 |
-47.33%
|
2025-06-18 |
8 |
胡晨曦
|
长城国瑞证券 |
医药生物 |
59.46%
|
62.99%
|
34.13%
|
3.45%
|
6 |
-27.10%
|
2025-05-26 |
9 |
刘浩
|
华创证券 |
医药生物 |
59.24%
|
58.96%
|
34.73%
|
20.00%
|
2 |
-47.33%
|
2025-06-24 |
10 |
赵海春
|
国金证券 |
医药生物 |
58.91%
|
65.10%
|
67.74%
|
-23.08%
|
2 |
-61.07%
|
2025-07-17 |
11 |
胡晨曦
|
长城国瑞证券 |
医药生物 |
58.86%
|
63.82%
|
39.02%
|
3.45%
|
6 |
-27.10%
|
2025-05-22 |
12 |
赵海春
|
国金证券 |
医药生物 |
58.28%
|
64.44%
|
67.84%
|
-23.08%
|
2 |
-61.07%
|
2025-07-18 |
13 |
韩世通
|
中信证券 |
医药生物 |
57.85%
|
58.94%
|
44.39%
|
-8.70%
|
6 |
-63.25%
|
2025-07-29 |
14 |
刘浩
|
华创证券 |
医药生物 |
57.77%
|
58.28%
|
34.06%
|
20.00%
|
2 |
-47.33%
|
2025-06-23 |
15 |
刘浩
|
华创证券 |
医药生物 |
57.71%
|
55.80%
|
23.66%
|
20.00%
|
2 |
-47.33%
|
2025-06-27 |
16 |
唐寅灏
|
中信证券 |
医药生物 |
57.63%
|
43.94%
|
41.58%
|
60.00%
|
12 |
-8.47%
|
2025-06-12 |
17 |
刘浩
|
华创证券 |
医药生物 |
57.58%
|
55.24%
|
29.18%
|
20.00%
|
2 |
-47.33%
|
2025-06-20 |
18 |
夏禹
|
国联民生 |
医药生物 |
57.51%
|
59.67%
|
29.37%
|
20.00%
|
7 |
-52.01%
|
2025-07-17 |
19 |
李安飞
|
广发证券 |
医药生物 |
57.32%
|
40.38%
|
32.20%
|
2.86%
|
1 |
-56.96%
|
2025-05-29 |
20 |
刘浩
|
华创证券 |
医药生物 |
57.17%
|
59.32%
|
27.27%
|
20.00%
|
2 |
-47.33%
|
2025-06-26 |